{"id":187776,"date":"2024-04-20T18:23:51","date_gmt":"2024-04-20T23:23:51","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/04\/prof-dr-thomas-rademacher-md-phd-ceo-co-founder-emergex-t-cell-priming-immunotherapies"},"modified":"2024-04-20T18:23:51","modified_gmt":"2024-04-20T23:23:51","slug":"prof-dr-thomas-rademacher-md-phd-ceo-co-founder-emergex-t-cell-priming-immunotherapies","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/04\/prof-dr-thomas-rademacher-md-phd-ceo-co-founder-emergex-t-cell-priming-immunotherapies","title":{"rendered":"Prof. Dr. Thomas Rademacher, MD, PhD \u2014 CEO &amp; Co-Founder, Emergex \u2014 T-Cell Priming Immunotherapies"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/IrTNozdZegE?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>T-Cell Priming Immunotherapies To Provide Broad And Robust, Long-Term Immunity \u2014 Prof. Dr. Thomas Rademacher, MD, PhD \u2014 CEO &amp; Co-Founder, Emergex Vaccines<\/p>\n<hr>\n<p>Professor Dr. Thomas Rademacher, MD, PhD, is CEO and Co-Founder of Emergex (<a href=\"https:\/\/emergexvaccines.com\/),\">https:\/\/emergexvaccines.com\/),<\/a> a company that has developed a novel nanoparticle-based vaccine technology to deliver synthetic viral fragments via microneedles on a skin-adhesive patch. Emergex\u2019s approach works on the principle of priming immune T-cells, opening the door for the development of universal vaccines against highly mutagenic viruses such as the seasonal flu and covid. T-cell priming offers a superior inoculation strategy over traditional vaccines, which rely on the body\u2019s generation of antibodies and fail to keep up with seasonal mutations.<\/p>\n<p>A serial entrepreneur, Professor Rademacher also serves as Emeritus Professor of Molecular Medicine at University College London (UCL) and is widely considered one of the founders of biotech from the early 1980s (having been involved in many of it\u2019s core disciplines \u2013 from recombinant proteins, to monoclonal antibodies, to glycobiology).<\/p>\n<p>Professor Rademacher has authored over 200 publications and 50 patents \u2013 19 of which are in the nanomedicine field. In addition to being a world leader in nanomedicine, he is also an expert in fetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia.<\/p>\n<p>Professor Rademacher was co-Founder of the field of Glycobiology and subsequent Glycobiology Institute in Oxford and co-founded Oxford GlycoSciences, the first of Oxford University\u2019s biotech spinouts, which, in 1998, was listed on the London Stock Exchange and reached a market capitalization of \u00a31.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd.<\/p>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2024\/04\/prof-dr-thomas-rademacher-md-phd-ceo-co-founder-emergex-t-cell-priming-immunotherapies\">Continue reading \u201cProf. Dr. Thomas Rademacher, MD, PhD \u2014 CEO &amp; Co-Founder, Emergex \u2014 T-Cell Priming Immunotherapies\u201d | &gt;<\/a><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"<p>T-Cell Priming Immunotherapies To Provide Broad And Robust, Long-Term Immunity \u2014 Prof. Dr. Thomas Rademacher, MD, PhD \u2014 CEO &amp; Co-Founder, Emergex Vaccines Professor Dr. Thomas Rademacher, MD, PhD, is CEO and Co-Founder of Emergex (https:\/\/emergexvaccines.com\/), a company that has developed a novel nanoparticle-based vaccine technology to deliver synthetic viral fragments via microneedles on a [\u2026]<\/p>\n","protected":false},"author":400,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,4],"tags":[],"class_list":["post-187776","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-nanotechnology"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/187776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/400"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=187776"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/187776\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=187776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=187776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=187776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}